Hope S. Rugo, MD, FASCO - From Evidence to Impact: Harnessing PI3K/AKT/mTOR Pathway Inhibitors to Improve Outcomes in HR+, HER2- MBC; Shedding Light on Mechanisms, Clinical Evidence, and Adverse Event Management

Go online to PeerView.com/DCY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.

An episode of the PeerView Clinical Pharmacology CME/CNE/CPE Video podcast, hosted by PVI, PeerView Institute for Medical Education, titled "Hope S. Rugo, MD, FASCO - From Evidence to Impact: Harnessing PI3K/AKT/mTOR Pathway Inhibitors to Improve Outcomes in HR+, HER2- MBC; Shedding Light on Mechanisms, Clinical Evidence, and Adverse Event Management" was published on April 3, 2026 and runs 43 minutes.

April 3, 2026 ·43m · PeerView Clinical Pharmacology CME/CNE/CPE Video

Summary

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCY865. CME/MOC/AAPA/IPCE credit will be available until March 22, 2027.From Evidence to Impact: Harnessing PI3K/AKT/mTOR Pathway Inhibitors to Improve Outcomes in HR+, HER2- MBC; Shedding Light on Mechanisms, Clinical Evidence, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

Episode Description